160 related articles for article (PubMed ID: 26718725)
41. Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor.
Asleh-Aburaya K; Sheffield BS; Kos Z; Won JR; Wang XQ; Gao D; Wolber R; Gilks CB; Bernard PS; Chia SK; Nielsen TO
Histopathology; 2017 Jan; 70(2):185-194. PubMed ID: 27402148
[TBL] [Abstract][Full Text] [Related]
42. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
43. Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.
Huang GS; Arend RC; Li M; Gunter MJ; Chiu LG; Horwitz SB; Goldberg GL
Am J Obstet Gynecol; 2009 Apr; 200(4):457.e1-5. PubMed ID: 19200930
[TBL] [Abstract][Full Text] [Related]
44. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
45. Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma.
Richmond AM; Blake EA; Torkko K; Smith EE; Spillman MA; Post MD
Int J Gynecol Cancer; 2017 Nov; 27(9):1895-1903. PubMed ID: 28704324
[TBL] [Abstract][Full Text] [Related]
46. Unusual Cutaneous Metastasis of Uterine Carcinosarcoma: A Case Report and Review of the Literature.
Clairwood M; Yasuda M; Belazarian L; Deng A
Am J Dermatopathol; 2016 May; 38(5):366-9. PubMed ID: 26675357
[TBL] [Abstract][Full Text] [Related]
47. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
48. Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
Etoh T; Nakai H
J Obstet Gynaecol Res; 2014 Mar; 40(3):820-5. PubMed ID: 24320058
[TBL] [Abstract][Full Text] [Related]
49. Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1ß, p53, PTEN, BAF250a, and COX-2.
Lai CR; Hsu CY; Chen YJ; Yen MS; Chao KC; Li AF
J Chin Med Assoc; 2013 Nov; 76(11):629-34. PubMed ID: 23962610
[TBL] [Abstract][Full Text] [Related]
50. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
Plum PS; Ulase D; Bollschweiler E; Chon SH; Berlth F; Zander T; Alakus H; Hölscher AH; Bruns CJ; Schallenberg S; Quaas A; Loeser H
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1731-1739. PubMed ID: 29974234
[TBL] [Abstract][Full Text] [Related]
51. Prognostic factors and adjuvant therapy in uterine carcinosarcoma.
Wu TI; Hsu KH; Huang HJ; Hsueh S; Chou HH; Tsai CS; Ho KC; Chao A; Chang TC; Lai CH
Eur J Gynaecol Oncol; 2008; 29(5):483-8. PubMed ID: 19051818
[TBL] [Abstract][Full Text] [Related]
52. Role of lymphovascular invasion and immunohistochemical expression of IMP3 in the risk stratification of superficially invasive pT1 esophageal adenocarcinoma.
Trivedi A; Cartun RW; Ligato S
Pathol Res Pract; 2014 Jul; 210(7):402-6. PubMed ID: 24726263
[TBL] [Abstract][Full Text] [Related]
53. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
54. Expression of aurora kinases: Predictor of tumor dissemination in uterine carcinosarcoma.
Han KH; Kim MA; Park NH
Histol Histopathol; 2017 Jul; 32(7):717-724. PubMed ID: 27779297
[TBL] [Abstract][Full Text] [Related]
55. Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma.
Van Arsdale AR; Arend RC; Cossio MJ; Erickson BK; Wang Y; Doo DW; Leath CA; Goldberg GL; Huang GS
Cancer Med; 2018 Mar; 7(3):616-625. PubMed ID: 29455465
[TBL] [Abstract][Full Text] [Related]
56. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
57. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
58. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study.
Sartori E; Bazzurini L; Gadducci A; Landoni F; Lissoni A; Maggino T; Zola P; La Face B
Gynecol Oncol; 1997 Oct; 67(1):70-5. PubMed ID: 9345359
[TBL] [Abstract][Full Text] [Related]
59. Rare uterine cancer: carcinosarcomas. Review from histology to treatment.
Artioli G; Wabersich J; Ludwig K; Gardiman MP; Borgato L; Garbin F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):98-104. PubMed ID: 25468677
[TBL] [Abstract][Full Text] [Related]
60. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
